drugset
drugset / Trial / NCT04462198

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss

NCT04462198 ↗

Phase 1/2 Completed 28 enrolled Contineum Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind study of PIPE-505, or placebo, in subjects with hearing loss associated with speech-in-noise impairment.

Timeline

Start
2020-10-15
Primary completion
2021-06-17
Completion
2021-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject PIPE-505 Unknown — Other

Indications

sensorineural hearing loss disorder